Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
Psyence Biomedical (NASDAQ: PBM) has strengthened its Scientific Advisory Board with the appointment of Dr. Dan J. Stein, Professor and Chair of Psychiatry at the University of Cape Town and Director of the South African Medical Research Council Unit on Risk & Resilience in Mental Disorders.
Dr. Stein joins existing SAB members including Chair Dr. Albert Garcia-Romeu (Johns Hopkins), Dr. Seth Feuerstein (Yale), and Dr. Clive Ward-Able (Medical Director). The company is currently conducting a Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and plans to advance development for Alcohol Use Disorder.
Dr. Stein brings significant expertise in psychopharmacology, with fellowship and residency training at Columbia University. His research has earned notable recognition, including the Max Hamilton Award and Ethics in Psychopharmacology Award from the International College of Neuropsychopharmacologicum.
Psyence Biomedical (NASDAQ: PBM) ha rafforzato il suo Consiglio Consultivo Scientifico con la nomina del Dr. Dan J. Stein, Professore e Direttore di Psichiatria presso l'Università di Città del Capo e Direttore dell'Unità del Consiglio di Ricerca Medica Sudafricano sui Rischi e la Resilienza nei Disturbi Mentali.
Il Dr. Stein si unisce ai membri esistenti del SAB, tra cui il Presidente Dr. Albert Garcia-Romeu (Johns Hopkins), Dr. Seth Feuerstein (Yale) e Dr. Clive Ward-Able (Direttore Medico). Attualmente, l'azienda sta conducendo un trial clinico di Fase IIb di psilocibina per il Disturbo di Adattamento in Cure Palliative e prevede di avanzare nello sviluppo per il Disturbo da Uso di Alcol.
Il Dr. Stein porta con sé una significativa esperienza in psicofarmacologia, con formazione di fellowship e residenza alla Columbia University. La sua ricerca ha ricevuto notevoli riconoscimenti, tra cui il Max Hamilton Award e l'Ethics in Psychopharmacology Award dal Collegio Internazionale di Neuropsicofarmacologia.
Psyence Biomedical (NASDAQ: PBM) ha fortalecido su Consejo Asesor Científico con la designación del Dr. Dan J. Stein, Profesor y Presidente de Psiquiatría en la Universidad de Ciudad del Cabo y Director de la Unidad del Consejo de Investigación Médica de Sudáfrica sobre Riesgo y Resiliencia en Trastornos Mentales.
El Dr. Stein se une a los miembros existentes del SAB, incluido el Presidente Dr. Albert Garcia-Romeu (Johns Hopkins), Dr. Seth Feuerstein (Yale) y Dr. Clive Ward-Able (Director Médico). Actualmente, la empresa está llevando a cabo un ensayo clínico de Fase IIb de psilocibina para el Trastorno de Adaptación en Cuidados Paliativos y planea avanzar en el desarrollo para el Trastorno por Uso de Alcohol.
El Dr. Stein aporta una experiencia significativa en psicofarmacología, con formación de fellowship y residencia en la Universidad de Columbia. Su investigación ha recibido un notable reconocimiento, incluido el Max Hamilton Award y el Ethics in Psychopharmacology Award del Colegio Internacional de Neuropsicofarmacología.
Psyence Biomedical (NASDAQ: PBM)는 Dr. Dan J. Stein을 과학 자문 위원회에 임명하여 강화했습니다. 그는 케이프타운 대학교 정신의학 교수이자 의사 및 남아프리카 의학 연구 위원회의 정신 장애의 위험 및 회복력에 관한 유닛의 이사입니다.
Dr. Stein은 기존 SAB 구성원인 의장 Dr. Albert Garcia-Romeu (존스 홉킨스), Dr. Seth Feuerstein (예일), Dr. Clive Ward-Able (의료 이사)와 함께합니다. 현재 회사는 완화 치료에서의 적응 장애를 위한 실로시빈 2b상 임상 시험을 진행 중이며 알코올 사용 장애의 개발을 진행할 계획입니다.
Dr. Stein은 콜롬비아 대학교에서 펠로우십 및 레지던시 교육을 받은 심리 약리학 분야의 전문 지식을 가지고 있습니다. 그의 연구는 맥스 해밀턴 상 및 국제 신경심리약리학회에서 수여하는 윤리 심리약리학 상을 포함하여 주목할만한 인정을 받았습니다.
Psyence Biomedical (NASDAQ: PBM) a renforcé son Conseil Consultatif Scientifique avec la nomination du Dr. Dan J. Stein, Professeur et Président de Psychiatrie à l'Université de Cape Town et Directeur de l'Unité du Conseil Sud-Africain de Recherche Médicale sur le Risque et la Résilience dans les Troubles Mentaux.
Le Dr. Stein rejoint les membres existants du SAB, y compris le Président Dr. Albert Garcia-Romeu (Johns Hopkins), Dr. Seth Feuerstein (Yale) et Dr. Clive Ward-Able (Directeur Médical). Actuellement, la société mène un essai clinique de Phase IIb sur la psilocybine pour le Trouble d'Adaptation en Soins Palliatifs et prévoit d'avancer le développement pour le Trouble de l'Usage de l'Alcool.
Le Dr. Stein apporte une expertise significative en psychopharmacologie, avec une formation de fellowship et de résidence à l'Université de Columbia. Ses recherches ont reçu une reconnaissance notable, y compris le Max Hamilton Award et le Ethics in Psychopharmacology Award du Collège International de Neuropsychopharmacologie.
Psyence Biomedical (NASDAQ: PBM) hat seinen Wissenschaftlichen Beirat durch die Ernennung von Dr. Dan J. Stein, Professor und Vorsitzender der Psychiatrie an der Universität Kapstadt sowie Direktor der Südafrikanischen Medizinischen Forschungsrats-Einheit für Risiko und Resilienz bei psychischen Störungen, verstärkt.
Dr. Stein tritt den bestehenden SAB-Mitgliedern bei, darunter der Vorsitzende Dr. Albert Garcia-Romeu (Johns Hopkins), Dr. Seth Feuerstein (Yale) und Dr. Clive Ward-Able (Ärztlicher Direktor). Das Unternehmen führt derzeit eine Phase-IIb-Studie zu Psilocybin bei Anpassungsstörungen in der Palliativversorgung durch und plant, die Entwicklung für Alkoholkonsumstörungen voranzutreiben.
Dr. Stein bringt umfangreiche Erfahrungen in der Psychopharmakologie mit, mit einer Fellowship- und Facharztausbildung an der Columbia University. Seine Forschung hat bemerkenswerte Anerkennung erhalten, einschließlich des Max Hamilton Award und des Ethics in Psychopharmacology Award vom International College of Neuropsychopharmacologicum.
- Phase IIb clinical trial of psilocybin actively progressing
- Expansion into second indication (Alcohol Use Disorder) planned
- Addition of highly credentialed expert (h-index >200) to Scientific Advisory Board
- Strong academic partnerships with Johns Hopkins, Yale, and UCT
- Early-stage clinical trials with no approved products yet
- Multiple indications increase development costs and risks
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies
New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein joins Dr. Albert Garcia-Romeu (Chair), Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Dr. Seth Feuerstein, Department of Psychiatry at Yale University, and Dr. Clive Ward-Able, Medical Director of Psyence Biomedical on the Company's SAB. The Company will discuss the role of the SAB in a corporate webinar scheduled for Thursday, April 10, 2025, at 12:00 p.m. EST.
"Dr. Stein brings decades of diverse clinical and scientific experience in the area of psychopharmacology and psychotherapy trials, and I could not be more excited to welcome him to our SAB," stated Dr. Neil Maresky, M.B.,B.Ch., Chief Executive Officer of Psyence Biomed. "While we continue in our Phase IIb clinical trial of psilocybin as a potential treatment for Adjustment Disorder in Palliative Care, we will also be advancing plans for our second development indication in Alcohol Use Disorder. With the objective guidance from our world-class SAB, I believe we are well positioned to introduce an entirely new class of psilocybin-based therapeutics to address significant unmet needs in mental health and addiction."
"Psychedelic therapies hold promise in psychiatry across a number of indications," stated Dr. Stein. "I am excited to join Psyence Biomed's SAB at this crucial time for the company and help guide their pioneering work with nature-derived psilocybin. I look forward to working alongside my fellow SAB members as Psyence Biomed advances and expands its pipeline of promising psilocybin-based therapeutic candidates."
Dr. Dan J. Stein is internationally recognized as an expert in psychopharmacology. He completed his fellowship and residency training at Columbia University and the New York State Psychiatric Institute. He is a clinician-scientist whose work has long focused on anxiety and related disorders, including obsessive-compulsive spectrum conditions and posttraumatic stress disorder. He has also mentored a range of other research, with publications spanning basic neuroscience, through clinical research, and on to public mental health. His research has had considerable influence (as evidenced by a Google h-index > 200), as has his mentorship (as evidenced by the career success of his postgraduate students and fellows). Awards for his work include the International College of Neuropsychopharmacologicum's Max Hamilton Award for his contributions to psychopharmacology, and its Ethics in Psychopharmacology Award.
Corporate Webinar
Psyence Biomed is pleased to announce that it will be hosting a corporate webinar with its executive team on Thursday, April 10, 2025, at 12:00 PM EST. This webinar will provide investors and stakeholders with a unique opportunity to engage directly with Psyence Biomed's leadership, ask questions, and gain valuable insights into the Company's ongoing clinical research and future initiatives. During the webinar, the executive team will also discuss the Company's broader vision for the future of psychedelic therapeutics. Investors and stakeholders are encouraged to attend and participate in this informative session.
To register, please access the following link: Psyence Biomed Corporate Webinar
About Psyence Biomed:
Psyence Biomedical Ltd. (NASDAQ: PBM) is one of the few vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
Investor Contact:
Michael Kydd
Investor Relations Advisor michael@psyencebiomed.com
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.
Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial and preparations for the Company's second development indication. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule and that topline data from this trial will be positive. There can be no assurance that the Company will continue to maintain compliance with Nasdaq's continued listing requirements.
There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence Biomed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence Biomed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence Biomed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomed's business and changes in Psyence Biomed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the "SEC") on January 24, 2025 and other documents filed by Psyence Biomed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence Biomed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244867
FAQ
What is the current status of Psyence Biomedical's (PBM) psilocybin clinical trials?
Who are the current members of Psyence Biomedical's (PBM) Scientific Advisory Board?
When is Psyence Biomedical's (PBM) next corporate webinar scheduled?
What therapeutic areas is Psyence Biomedical (PBM) targeting with its psilocybin treatments?
